NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free DAWN Stock Alerts $16.52 +0.73 (+4.62%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$15.75▼$16.8950-Day Range$13.56▼$17.4652-Week Range$9.67▼$17.85Volume779,701 shsAverage Volume596,999 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$40.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Day One Biopharmaceuticals alerts: Email Address Day One Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside145.8% Upside$40.60 Price TargetShort InterestBearish16.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 11 Articles This WeekInsider TradingSelling Shares$722,960 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.66) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.89 out of 5 starsMedical Sector642nd out of 938 stocksPharmaceutical Preparations Industry292nd out of 425 stocks 3.3 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.60, Day One Biopharmaceuticals has a forecasted upside of 145.8% from its current price of $16.52.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.31% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 0.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 3.0 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $722,960.00 in company stock.Percentage Held by InsidersOnly 8.80% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.66) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -6.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesMarch 27, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesMarch 27, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given "Overweight" Rating at Piper SandlerMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)March 24, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 3.8%March 23, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by AnalystsMarch 17, 2024 | finance.yahoo.comDAWN Jul 2024 17.500 callMarch 15, 2024 | finance.yahoo.comCompanies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In GrowthMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)February 28, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Day One Biopharmaceuticals Amid Tovorafenib’s Promising Prospects and Financial StabilityFebruary 28, 2024 | finance.yahoo.comDay One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial ResultsFebruary 27, 2024 | finanznachrichten.deDay One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressFebruary 27, 2024 | edition.cnn.comDay One Biopharmaceuticals, Inc.February 26, 2024 | globenewswire.comDay One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressFebruary 6, 2024 | benzinga.comDay One Biopharmaceutical Stock (NASDAQ:DAWN), Short Interest ReportFebruary 1, 2024 | seekingalpha.comNavigating Day One Biopharmaceuticals' Financial Health And Clinical ProspectsDecember 19, 2023 | finance.yahoo.comDay One to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNovember 27, 2023 | finance.yahoo.comMilei to Send ‘Shock’ Package to Argentina’s Congress on Day OneNovember 14, 2023 | finance.yahoo.comDay One to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 9, 2023 | morningstar.comDay One Biopharmaceuticals IncNovember 8, 2023 | markets.businessinsider.comDay One Biopharmaceuticals: High Confidence in Tovorafenib’s FDA Approval and Promising Expansion StrategyNovember 6, 2023 | msn.comDay One Biopharmaceuticals GAAP EPS of -$0.54November 6, 2023 | finance.yahoo.comDay One Reports Third Quarter 2023 Financial Results and Corporate ProgressNovember 6, 2023 | finance.yahoo.comDay One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate ProgressOctober 30, 2023 | techcrunch.comApple’s Journal app has arrived – here’s what’s good and badOctober 30, 2023 | markets.businessinsider.comDay One Biopharma Gets FDA Priority Review On NDA For Tovorafenib - Quick FactsSee More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$40.60 High Stock Price Target$50.00 Low Stock Price Target$34.00 Potential Upside/Downside+147.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.67% Return on Assets-48.30% Debt Debt-to-Equity RatioN/A Current Ratio12.72 Quick Ratio12.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book4.12Miscellaneous Outstanding Shares87,390,000Free Float79,695,000Market Cap$1.43 billion OptionableOptionable Beta-1.48 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer Dr. Elly Barry M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULAbCellera BiologicsNASDAQ:ABCLAkero TherapeuticsNASDAQ:AKROProthenaNASDAQ:PRTAMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsSamuel C BlackmanSold 10,000 sharesTotal: $160,100.00 ($16.01/share)Vanguard Group Inc.Bought 139,992 shares on 3/11/2024Ownership: 5.458%Wellington Management Group LLPBought 91,393 shares on 3/5/2024Ownership: 0.239%Fisher Asset Management LLCBought 32,238 shares on 3/5/2024Ownership: 0.078%Goldman Sachs Group Inc.Bought 472,654 shares on 3/1/2024Ownership: 2.425%View All Insider TransactionsView All Institutional Transactions DAWN Stock Analysis - Frequently Asked Questions Should I buy or sell Day One Biopharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares. View DAWN analyst ratings or view top-rated stocks. What is Day One Biopharmaceuticals' stock price target for 2024? 7 analysts have issued 1 year price objectives for Day One Biopharmaceuticals' stock. Their DAWN share price targets range from $34.00 to $50.00. On average, they predict the company's stock price to reach $40.60 in the next year. This suggests a possible upside of 145.8% from the stock's current price. View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts. How have DAWN shares performed in 2024? Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN stock has increased by 13.2% and is now trading at $16.52. View the best growth stocks for 2024 here. When is Day One Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our DAWN earnings forecast. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its earnings results on Monday, February, 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.07. What ETFs hold Day One Biopharmaceuticals' stock? ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an IPO on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.48%), Vanguard Group Inc. (5.46%), Franklin Resources Inc. (4.87%), Braidwell LP (4.84%), Price T Rowe Associates Inc. MD (2.66%) and Price T Rowe Associates Inc. MD (2.66%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DAWN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.